Mannkind Corporation Participating at Upcoming Conferences
MannKind Corporation (Nasdaq: MNKD) announced its participation in two upcoming conferences, featuring CEO Michael Castagna, PharmD as a presenter. The events include the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, and the 2021 Cantor Global Virtual Healthcare Conference on September 27, 2021. Interested individuals can access live webcasts and replays on the company’s website for 14 days post-event. MannKind is known for developing inhaled therapeutic products, including Afrezza, an FDA-approved inhaled insulin available in the U.S. and Brazil.
- None.
- None.
WESTLAKE VILLAGE, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD.
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit – Wednesday, September 22, 2021 at 2:55 pm – 3:35 pm (ET)
- 2021 Cantor Global Virtual Healthcare Conference – Monday, September 27, 2021 at 11:20 am – 11:50 am (ET)
Interested parties can access a link to the live webcast of the presentations from the Events & Presentations section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations. The webcast replay may be accessed at the same location for 14 days following the live presentation.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.
Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
FAQ
When is MannKind participating in the Oppenheimer Fall Healthcare Life Sciences Summit?
What is the date and time of the Cantor Global Virtual Healthcare Conference for MannKind?
Who is presenting for MannKind at the upcoming conferences?
How can I access the live webcast of MannKind's presentations?
What product is MannKind known for developing?
